Hoth Therapeutics, Inc. Announces Positive Results From Pilot Study of BioLexa on Diabetic Skin Ulcers

New York, NY – July 22, 2019 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initial results of its Pilot Study of BioLexa application on diabetic skin […]